Merck & Co., Inc. (SNSE:MRK)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 245.24T +29.8% |
| Revenue (ttm) | 61.15T +2.9% |
| Net Income | 8.31T -48.8% |
| EPS | 3,324.75 -48.0% |
| Shares Out | n/a |
| PE Ratio | 29.52 |
| Forward PE | 17.90 |
| Dividend | 3,080.85 (2,617.33%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 117.71 |
| Day's Range | n/a |
| 52-Week Range | 76.66 - 122.10 |
| Beta | 0.39 |
| RSI | 69.46 |
| Earnings Date | Apr 30, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoat...
Merck reinstated with a Neutral at Citi
Citi analyst Geoff Meacham reinstated coverage of Merck (MRK) with a Neutral rating and $125 price target Citi views the company’s Q1 report as solid but wants to see positive
Merck Animal Health selects Agentforce Life Sciences for Customer Experiences
Salesforce (CRM) and Merck Animal Health (MRK) announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experie...
Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
SAN FRANCISCO & RAHWAY, N.J.--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of...
Merck completes Terns Pharmaceuticals acquisition
Merck (MRK) announced the completion of the acquisition of Terns Pharmaceuticals (TERN). TERN-701 was recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the...
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Te...
Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk
Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and resistance zones now shape the outlook for a deeper correction.
Merck price target raised to $112 from $109 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck (MRK) to $112 from $109 and keeps an Equal Weight rating on the shares. The company reported a
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
Mizuho reiterated an Outperform rating and $45 price target on Enliven (ELVN) after Merck (MRK) noted during its Q1 call that it believes Terns’ (TERN) TERN-701 major molecular response “will
Merck & Co. Earnings Call Transcript: Q1 2026
Q1 revenue grew 5% year-over-year to $16.3B, led by oncology and animal health, but a $9B one-time charge for Sedera resulted in a reported loss. Guidance for 2026 was raised, with continued investment in launches and pipeline, and the Terns acquisition expected to further diversify growth.
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NC...
Options Volatility and Implied Earnings Moves Today, April 30, 2026
Today, several major companies are expected to report earnings: Altria Group (MO), Apple (AAPL), Bristol-Myers Squibb (BMY), Caterpillar (CAT), Eli Lilly & Co (LLY), Mastercard (MA), Merck & Company (...
Merck Sales Rise on Continued Keytruda Growth
Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow.
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales guidan...
Merck posts quarterly loss due to Cidara charge, sales rise 5%
Merck & Co on Thursday reported a loss for the first quarter as an acquisition-related charge offset a 5% increase in product sales driven by cancer and respiratory drugs.
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results.
Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional ba...
Oppenheimer downgrades Terns Pharmaceuticals to Perform following Merck deal
As previously reported, Oppenheimer downgraded Terns Pharmaceuticals to Perform from Outperform and removed the firm’s price target of $58 on the stock. Oppenheimer says Merck’s (MRK) acquisition of T...
Merck announces expiration of HSR waiting period to acquire Terns Pharmaceuticals
Merck (MRK) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Merck’s pending acquisition of Terns Pharmaceuticals (TERN)...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act o...
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growth LAS VEGAS, April 22, 2026 /PRNewswire/ -- Clou...
Merck to partner with Google Cloud on AI initiatives
Drugmaker Merck & Co said on Wednesday it will partner with Google Cloud to build up its artificial intelligence capabilities, investing as much as $1 billion with Google over a number of years to fu...
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer treatment that could be valued at more tha...
FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™...